Expertise Therapeutic Areas

Hepatology and Gastrointestinal

Accelsiors: Championing Hepatology Research, Enhancing Global Health.

Collectively, GI disorders have a significant impact on global health. GI disorders are highly prevalent worldwide.

Accelsiors is a recognized CRO in Gastrointestinal field, with special focus on Hepatology, with a very robust, 20+ years of experience in the field. Hepatic disorders are prevalent worldwide. We have conducted several trials of all phases in indications like different forms of viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), cirrhosis, hepatic encephalopathy, hepatocellular carcinoma, autoimmune liver diseases (such as autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis), and genetic liver diseases (such as hemochromatosis and Wilson disease).

Accelsiors stands as a trusted leader in Gastrointestinal and Hepatology research, leveraging our extensive 20+ year experience in executing trials across all phases for a wide array of liver and GI conditions, contributing to enhanced understanding and improved management of these globally prevalent and impactful disorders.

Conditions such as liver disease, including viral hepatitis and liver cirrhosis, are significant causes of mortality. Gastrointestinal cancers, including those of the esophagus, stomach, liver, pancreas, and colorectal region, are leading causes of cancer-related deaths.

Ask Accelsiors' Clinical Trial Regulatory Experts
Human body digestive system anatomy. 3d illustration

GI disorders can cause significant disability and harm the quality of life. Conditions like PBC, PSC, IBS, Crohn’s disease, and ulcerative colitis can result in chronic symptoms, recurrent flare-ups, and impairments in daily functioning and overall well-being. The burden and epidemiology of GI disorders may vary across different regions and populations. Some conditions, like certain liver diseases, are more prevalent in specific geographic areas due to viral hepatitis prevalence, lifestyle factors, or environmental exposures. Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, also exhibit regional variations in incidence and prevalence.

Our approach to Hepatology and GI Disorders
  • Executed studies from phase I (first in human) to phase III (registration) trials
  • Detailed database of highly qualified hepatology sites worldwide
  • Access to patients around the globe
  • Significant experience in translational science in the field of hepatology and GI disorders
  • Depth of experience with population PK analysis in adult and pediatric population, including PK/PD modelling
Experience in Hepatology
Experience in GI Disorders
Experience by Age Groups
Experience by Trial Phases

Let us accelerate your clinical drug development program!